News Focus
News Focus
Followers 24
Posts 3957
Boards Moderated 0
Alias Born 07/20/2006

Re: indigokid post# 16419

Tuesday, 01/24/2017 7:07:51 AM

Tuesday, January 24, 2017 7:07:51 AM

Post# of 20689

Any thoughts on which other one might have been dropped from Mylan partnership?


Reviewing each one listed, I cannot haphazard a guess. However, I did decifer that MNTA has the PATENTED expertise to make interchangeables anywhere/anyhow. Here's a "cursory" list from the following branded drugs - as stated:

METHODS OF EVALUATING AND MAKING BIOLOGICS

In one embodiment, the target biologic is selected from the products marketed as:

Humira®, Avastin®; Rituxan®; Mabthera®; Campath®; Herceptin®; Xolair®; Prolia®;

Vectibix®; ReoPro®; Zenapax®; Simulect®; Synagis®; Remicade®; Mylotarg®; Campath®; Raptiva®; Zevalin®; Erbitux®; Tysabri®; Lucentis®; Soliris®; Cimzia®; Ilaris®; Arzerra®; Bexxar®; Simponi®; Prolia®; Xgeva®; Actemra®; Benlysta®; Adcetris®; Yervoy®.


https://worldwide.espacenet.com/publicationDetails/description?CC=WO&NR=2013181576A2&KC=A2&FT=D&ND=3&date=20131205&DB=EPODOC&locale=en_EP

They've hit the MOTHERLODE here!! Is this a takeover, or what?!